Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature
Severe cutaneous adverse drug reactions (SCAR) such as the Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DIHS) can be induced by a plethora of medications. The field of pharmacogenomics aims...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/11/2/71 |
| _version_ | 1797407251256836096 |
|---|---|
| author | Ogechi Ikediobi Jeremy A. Schneider |
| author_facet | Ogechi Ikediobi Jeremy A. Schneider |
| author_sort | Ogechi Ikediobi |
| collection | DOAJ |
| description | Severe cutaneous adverse drug reactions (SCAR) such as the Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DIHS) can be induced by a plethora of medications. The field of pharmacogenomics aims to prevent severe adverse drug reactions by using our knowledge of the inherited or acquired genetic risk of drug metabolizing enzymes, drug targets, or the human leukocyte antigen (HLA) genotype. Dermatologists are experts in the diagnosis and management of severe cutaneous adverse drug reactions (SCAR) in both the inpatient and outpatient setting. However, most dermatologists in the US have not focused on the prevention of SCAR. Therefore, this paper presents a case series and review of the literature highlighting salient examples of how dermatologists can apply pharmacogenomics in the diagnosis and especially in the prevention of SCAR induced by allopurinol and sulfamethoxazole/trimethoprim, two commonly prescribed medications. |
| first_indexed | 2024-03-09T03:38:07Z |
| format | Article |
| id | doaj.art-140c6ed117d44feba61b598ff2efe899 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T03:38:07Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-140c6ed117d44feba61b598ff2efe8992023-12-03T14:44:21ZengMDPI AGJournal of Personalized Medicine2075-44262021-01-011127110.3390/jpm11020071Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the LiteratureOgechi Ikediobi0Jeremy A. Schneider1Department of Dermatology, University of California, San Diego, CA 92093, USADepartment of Dermatology, University of California, San Diego, CA 92093, USASevere cutaneous adverse drug reactions (SCAR) such as the Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DIHS) can be induced by a plethora of medications. The field of pharmacogenomics aims to prevent severe adverse drug reactions by using our knowledge of the inherited or acquired genetic risk of drug metabolizing enzymes, drug targets, or the human leukocyte antigen (HLA) genotype. Dermatologists are experts in the diagnosis and management of severe cutaneous adverse drug reactions (SCAR) in both the inpatient and outpatient setting. However, most dermatologists in the US have not focused on the prevention of SCAR. Therefore, this paper presents a case series and review of the literature highlighting salient examples of how dermatologists can apply pharmacogenomics in the diagnosis and especially in the prevention of SCAR induced by allopurinol and sulfamethoxazole/trimethoprim, two commonly prescribed medications.https://www.mdpi.com/2075-4426/11/2/71pharmacogenomicsdermatologydrug-induced hypersensitivity syndromeStevens–Johnson syndrometoxic epidermal necrolysissevere cutaneous adverse drug reaction |
| spellingShingle | Ogechi Ikediobi Jeremy A. Schneider Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature Journal of Personalized Medicine pharmacogenomics dermatology drug-induced hypersensitivity syndrome Stevens–Johnson syndrome toxic epidermal necrolysis severe cutaneous adverse drug reaction |
| title | Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature |
| title_full | Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature |
| title_fullStr | Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature |
| title_full_unstemmed | Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature |
| title_short | Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature |
| title_sort | pharmacogenomics of allopurinol and sulfamethoxazole trimethoprim case series and review of the literature |
| topic | pharmacogenomics dermatology drug-induced hypersensitivity syndrome Stevens–Johnson syndrome toxic epidermal necrolysis severe cutaneous adverse drug reaction |
| url | https://www.mdpi.com/2075-4426/11/2/71 |
| work_keys_str_mv | AT ogechiikediobi pharmacogenomicsofallopurinolandsulfamethoxazoletrimethoprimcaseseriesandreviewoftheliterature AT jeremyaschneider pharmacogenomicsofallopurinolandsulfamethoxazoletrimethoprimcaseseriesandreviewoftheliterature |